Healthy areas in the lung tend to compensate for sick areas, therefor severity of respiratory diseases is often underestimated by conventional lung function tests like spirometry, which can indicate normal lung function despite declining lung health. Quantitative HRCT techniques such as FRI yields more accurate regional information that is clinically relevant for early and correct diagnosis and to optimize treatments for individual patients.
The FDA provided market clearance to Fluidda for its Broncholab platform in March 2020. Broncholab provides several Functional Respiratory Imaging (FRI) parameters to physicians via an online platform to assist in diagnosing and monitoring of respiratory diseases. “Functional Respiratory Imaging has been used in clinical trials for many years and has proven its value time and time again.” Dr. Jan De Backer, Fluidda’s CEO, states. “Broncholab now extends these capabilities into clinical practice which is a tremendous step forward in our quest for better respiratory care. We are living in a time where respiratory viruses cause significant disruption to daily life with high associated cost. We are striving to better understand respiratory illnesses with our novel technology to be more prepared for the next viral outbreak and to deal with the increased number of patients with lung diseases worldwide.”
The Canadian regulatory authorities (Health Canada) granted Fluidda permission to use Broncholab. This authorization is valid for so long as the Interim Order Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19 is in effect.